Insider Trading activities of Ariad Pharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ariad Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ariad Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Ariad Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is ARIA. The reporting company's CIK number is 884731.
The total value of stock buying since 2005 is $9,530,946.
The total value of stock sales since 2005 is $52,752,828.
The total value of stock option exercises since 2005 is $11,507,365.


Go to page:  1   2   3 
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Ariad Pharmaceuticals Inc (ARIA).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-01 0 $0 32,000 $760,960 98,600 $250,240
2016-10 0 $0 67,022 $825,575 0 $0
2016-09 0 $0 88,119 $1,087,245 86,869 $464,265
2016-08 0 $0 44,436 $466,033 25,000 $192,250
2016-07 0 $0 79,708 $607,846 128,022 $237,703
2016-06 0 $0 214,830 $1,739,251 203,985 $963,931
2016-05 26,990 $199,995 17,762 $143,428 0 $0
2016-04 0 $0 21,409 $157,869 66,002 $0
2016-03 0 $0 145,578 $908,483 201,416 $51,450
2016-02 61,099 $299,996 105,601 $508,813 260,331 $0
2015-12 0 $0 0 $0 602,500 $0
2015-09 0 $0 45,696 $302,440 132,500 $0
2015-08 0 $0 34,126 $341,260 0 $0
2015-07 0 $0 31,800 $271,606 99,600 $0
2015-05 0 $0 60,000 $528,000 60,000 $453,600
2015-04 0 $0 123,766 $1,175,777 0 $0
2015-03 0 $0 116,788 $1,022,831 358,114 $1,284,919
2015-02 25,000 $170,850 154,638 $1,060,651 341,373 $174,319
2015-01 27,600 $171,423 0 $0 0 $0
2014-12 27,600 $174,484 0 $0 0 $0
2014-11 27,600 $170,013 1,749 $12,243 0 $0
2014-10 27,600 $144,167 0 $0 0 $0
2014-09 27,600 $171,821 109,346 $679,851 234,075 $1,121,049
2014-08 852,600 $4,970,098 0 $0 0 $0
2014-07 0 $0 0 $0 99,600 $0
2014-06 0 $0 3,713 $25,612 0 $0
2014-04 0 $0 18,950 $155,603 96,667 $0
2014-03 0 $0 16,734 $132,016 172,083 $0
2013-12 0 $0 29,325 $150,755 145,000 $0
2013-11 0 $0 0 $0 35,250 $0
2013-09 0 $0 8,449 $185,878 25,000 $0
2013-08 0 $0 118,759 $2,179,178 33,000 $128,700
2013-07 0 $0 256,600 $5,163,490 231,200 $0
2013-06 0 $0 11,200 $201,622 0 $0
2013-05 0 $0 92,498 $1,672,365 0 $0
2013-04 0 $0 134,533 $2,423,150 107,832 $0
2013-03 0 $0 221,586 $4,555,916 396,334 $0
2013-01 0 $0 25,000 $501,900 57,939 $338,769
2012-12 0 $0 10,500 $213,213 188,750 $141,210
2012-10 0 $0 42,500 $1,041,630 7,500 $9,750
2012-09 0 $0 145,705 $3,301,055 104,925 $422,856
2012-08 0 $0 74,843 $1,496,900 56,844 $331,785
2012-07 0 $0 123,812 $2,303,353 72,212 $343,070
2012-06 0 $0 46,765 $784,775 64,691 $292,598
2012-05 0 $0 95,580 $1,621,724 120,450 $590,685
2012-04 0 $0 156,357 $2,399,896 158,501 $268,615
2012-03 0 $0 356,677 $5,550,529 918,936 $320,549
2012-02 0 $0 169,011 $2,532,072 172,611 $697,322
2012-01 0 $0 30,000 $451,606 0 $0
2011-07 0 $0 0 $0 20,837 $100,017
2011-06 0 $0 0 $0 120,000 $678,000
2011-05 0 $0 0 $0 25,000 $141,250
2011-04 0 $0 0 $0 305,000 $0
2011-03 0 $0 25,000 $175,275 287,005 $0
2011-02 0 $0 25,000 $161,925 0 $0
2011-01 0 $0 25,000 $134,325 0 $0
2010-12 0 $0 25,000 $125,125 0 $0
2010-10 13,000 $48,100 0 $0 0 $0
2010-05 0 $0 29,548 $124,709 0 $0
2009-10 0 $0 70,000 $151,550 70,000 $52,500
2009-08 1,720,000 $3,009,999 0 $0 0 $0
2008-01 0 $0 0 $0 40,000 $0
2007-07 0 $0 0 $0 113,772 $497,860
2007-06 0 $0 0 $0 85,000 $258,399
2007-05 0 $0 0 $0 224,455 $448,910
2007-01 0 $0 0 $0 10,000 $0
2006-03 0 $0 0 $0 25,933 $108,334
2006-02 0 $0 26,077 $170,520 34,000 $142,460
2006-01 0 $0 10,000 $64,999 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Ariad Pharmaceuticals Inc insiders (ARIA)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-01-13 Panayiotopoulos Paris (President and CEO) Option Ex 66,600 .00 0
2017-01-09 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 32,000 23.78 760,960
2017-01-09 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 32,000 7.82 250,240
2016-10-24 Clackson Timothy P (President, R&D, CSO) Sale 19,638 9.56 187,739
2016-10-03 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 47,384 13.46 637,836
2016-09-28 Clackson Timothy P (President, R&D, CSO) Sale 8,750 13.98 122,307
2016-09-26 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 10,000 .00 0
2016-09-26 Clackson Timothy P (President, R&D, CSO) Option Ex 17,500 .00 0
2016-09-22 Clackson Timothy P (President, R&D, CSO) Sale 20,000 13.43 268,540
2016-09-15 Clackson Timothy P (President, R&D, CSO) Sale 59,369 11.73 696,398
2016-09-15 Clackson Timothy P (President, R&D, CSO) Option Ex 59,369 7.82 464,265
2016-08-22 Clackson Timothy P (President, R&D, CSO) Sale 19,436 10.47 203,533
2016-08-12 Clackson Timothy P (President, R&D, CSO) Sale 25,000 10.50 262,500
2016-08-12 Clackson Timothy P (President, R&D, CSO) Option Ex 25,000 7.69 192,250
2016-07-22 Clackson Timothy P (President, R&D, CSO) Sale 18,286 8.11 148,226
2016-07-13 Panayiotopoulos Paris (President and CEO) Option Ex 66,600 .00 0
2016-07-01 Clackson Timothy P (President, R&D, CSO) Sale 61,422 7.48 459,620
2016-07-01 Clackson Timothy P (President, R&D, CSO) Option Ex 61,422 3.87 237,703
2016-06-28 Cole Hugh M (SVP, Chief Business Officer) Sale 6,012 7.05 42,384
2016-06-27 Cole Hugh M (SVP, Chief Business Officer) Option Ex 19,166 .00 0
2016-06-22 Clackson Timothy P (President, R&D, CSO) Sale 23,999 7.28 174,640
2016-06-15 Lavidas Athanese Sale 46,250 8.24 381,146
2016-06-15 Lavidas Athanese Option Ex 46,250 6.25 289,062
2016-06-14 Radaelli Massimo Sale 6,250 8.13 50,831
2016-06-14 Radaelli Massimo Option Ex 6,250 4.91 30,687
2016-06-14 Lavidas Athanese Sale 20,000 8.14 162,860
2016-06-14 Lavidas Athanese Option Ex 20,000 6.44 128,800
2016-06-13 Radaelli Massimo Sale 79,731 8.25 657,860
2016-06-13 Radaelli Massimo Option Ex 79,731 5.39 429,989
2016-06-13 Lavidas Athanese Sale 10,000 8.21 82,050
2016-06-13 Lavidas Athanese Option Ex 10,000 5.49 54,900
2016-06-10 Radaelli Massimo Sale 22,588 8.30 187,480
2016-06-10 Radaelli Massimo Option Ex 22,588 1.35 30,493
2016-05-23 Clackson Timothy P (President, R&D, CSO) Sale 17,762 8.07 143,428
2016-05-12 Panayiotopoulos Paris (President and CEO) Buy 26,990 7.41 199,995
2016-04-29 Cantor Maria E (SVP, Corporate Affairs) Option Ex 13,334 .00 0
2016-04-29 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 17,334 .00 0
2016-04-29 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 17,334 .00 0
2016-04-29 Duvall Martin J (EVP, CCO) Option Ex 18,000 .00 0
2016-04-22 Clackson Timothy P (President, R&D, CSO) Sale 21,409 7.37 157,869
2016-03-22 Clackson Timothy P (President, R&D, CSO) Sale 23,834 6.58 156,875
2016-03-21 Haluska Frank (SVP, Clinical R&D, CMO) Sale 3,575 6.47 23,115
2016-03-21 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 4,000 6.47 25,872
2016-03-21 Fitzgerald Edward M (Executive VP) Sale 5,417 6.47 35,037
2016-03-21 Berstein David L (SVP, Chief IP Counsel) Sale 2,375 6.47 15,356
2016-03-19 Cantor Maria E (SVP, Corporate Affairs) Sale 3,575 6.46 23,101
2016-03-19 Cantor Maria E (SVP, Corporate Affairs) Option Ex 6,500 .00 0
2016-03-19 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 6,500 .00 0
2016-03-19 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 8,000 .00 0
2016-03-19 Duvall Martin J (EVP, CCO) Sale 4,000 6.47 25,868
2016-03-19 Duvall Martin J (EVP, CCO) Option Ex 8,000 .00 0
2016-03-19 Fitzgerald Edward M (Executive VP) Option Ex 10,833 .00 0
2016-03-19 Clackson Timothy P (President, R&D, CSO) Sale 5,417 6.47 35,037
2016-03-19 Clackson Timothy P (President, R&D, CSO) Option Ex 10,833 .00 0
2016-03-19 Berstein David L (SVP, Chief IP Counsel) Option Ex 4,750 .00 0
2016-03-16 Cole Hugh M (SVP, Chief Business Officer) Option Ex 7,500 6.21 46,575
2016-03-15 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 3,750 1.30 4,875
2016-03-03 Cantor Maria E (SVP, Corporate Affairs) Sale 9,625 6.12 58,866
2016-03-03 Haluska Frank (SVP, Clinical R&D, CMO) Sale 10,588 6.11 64,735
2016-03-03 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 9,625 6.12 58,856
2016-03-03 Duvall Martin J (EVP, CCO) Sale 9,625 6.12 58,866
2016-03-03 Fitzgerald Edward M (Executive VP, CFO) Sale 9,625 6.12 58,866
2016-03-03 Clackson Timothy P (President, R&D, CSO) Sale 9,625 6.12 58,866
2016-03-03 Berstein David L (SVP, Chief IP Counsel) Sale 9,625 6.12 58,885
2016-03-02 Clackson Timothy P (President, R&D, CSO) Sale 25,047 6.00 150,282
2016-03-01 Cantor Maria E (SVP, Corporate Affairs) Option Ex 19,250 .00 0
2016-03-01 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 19,250 .00 0
2016-03-01 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 19,250 .00 0
2016-03-01 Duvall Martin J (EVP, CCO) Option Ex 19,250 .00 0
2016-03-01 Fitzgerald Edward M (Executive VP, CFO) Option Ex 19,250 .00 0
2016-03-01 Clackson Timothy P (President, R&D, CSO) Option Ex 19,250 .00 0
2016-03-01 Berstein David L (SVP, Chief IP Counsel) Option Ex 19,250 .00 0
2016-02-18 Desrosier Thomas (EVP, General Counsel) Option Ex 55,000 .00 0
2016-02-01 Panayiotopoulos Paris (President and CEO) Buy 61,099 4.91 299,996
2016-02-01 Cantor Maria E (SVP, Corporate Affairs) Sale 16,133 4.87 78,551
2016-02-01 Cantor Maria E (SVP, Corporate Affairs) Option Ex 29,333 .00 0
2016-02-01 Haluska Frank (SVP, Clinical R&D, CMO) Sale 16,133 4.81 77,583
2016-02-01 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 29,333 .00 0
2016-02-01 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 14,667 4.81 70,548
2016-02-01 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 29,333 .00 0
2016-02-01 Duvall Martin J (EVP, CCO) Sale 14,667 4.81 70,577
2016-02-01 Duvall Martin J (EVP, CCO) Option Ex 29,333 .00 0
2016-02-01 Fitzgerald Edward M (Executive VP, CFO) Sale 14,667 4.81 70,518
2016-02-01 Fitzgerald Edward M (Executive VP, CFO) Option Ex 29,333 .00 0
2016-02-01 Clackson Timothy P (President, R&D, CSO) Sale 14,667 4.81 70,518
2016-02-01 Clackson Timothy P (President, R&D, CSO) Option Ex 29,333 .00 0
2016-02-01 Berstein David L (SVP, Chief IP Counsel) Sale 14,667 4.81 70,518
2016-02-01 Berstein David L (SVP, Chief IP Counsel) Option Ex 29,333 .00 0
2015-12-31 Berger Harvey J M D (Chairman & CEO) Option Ex 602,500 .00 0
2015-09-28 Cantor Maria E (SVP, Corporate Affairs) Sale 5,000 6.46 32,325
2015-09-28 Haluska Frank (SVP, Clinical R&D, CMO) Sale 5,500 6.46 35,502
2015-09-28 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 5,000 6.46 32,315
2015-09-28 Duvall Martin J (EVP, CCO) Sale 5,000 6.46 32,315
2015-09-28 Fitzgerald Edward M (Executive VP, CFO) Sale 8,750 6.46 56,551
2015-09-28 Clackson Timothy P (President, R&D, CSO) Sale 8,750 6.46 56,560
2015-09-28 Berstein David L (SVP, Chief IP Counsel) Sale 5,000 6.46 32,315
2015-09-24 Cantor Maria E (SVP, Corporate Affairs) Option Ex 10,000 .00 0
2015-09-24 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 10,000 .00 0
2015-09-24 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 10,000 .00 0
2015-09-24 Duvall Martin J (EVP, CCO) Option Ex 10,000 .00 0
2015-09-24 Fitzgerald Edward M (Executive VP, CFO) Option Ex 17,500 .00 0
2015-09-24 Clackson Timothy P (President, R&D, CSO) Option Ex 17,500 .00 0
2015-09-24 Berstein David L (SVP, Chief IP Counsel) Option Ex 10,000 .00 0
2015-09-24 Berger Harvey J M D (Chairman & CEO) Option Ex 47,500 .00 0
2015-09-01 Cantor Maria E (SVP, Corporate Affairs) Sale 2,696 9.11 24,557
2015-08-28 Cantor Maria E (SVP, Corporate Affairs) Sale 1,268 10.00 12,680
2015-08-28 Fitzgerald Edward M (Executive VP, CFO) Sale 32,858 10.00 328,580
2015-07-16 Cantor Maria E (SVP, Corporate Affairs) Sale 4,000 8.54 34,160
2015-07-16 Haluska Frank (SVP, Clinical R&D, CMO) Sale 4,400 8.54 37,575
2015-07-16 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 4,000 8.54 34,164
2015-07-16 Duvall Martin J (EVP, CCO) Sale 1,400 8.54 11,955
2015-07-16 Fitzgerald Edward M (Executive VP, CFO) Sale 7,000 8.54 59,794
2015-07-16 Clackson Timothy P (President, R&D, CSO) Sale 7,000 8.54 59,794
2015-07-16 Berstein David L (SVP, Chief IP Counsel) Sale 4,000 8.54 34,164
2015-07-15 Cantor Maria E (SVP, Corporate Affairs) Option Ex 8,000 .00 0
2015-07-15 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 8,000 .00 0
2015-07-15 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 8,000 .00 0
2015-07-15 Duvall Martin J (EVP, CCO) Option Ex 2,800 .00 0
2015-07-15 Fitzgerald Edward M (Executive VP, CFO) Option Ex 14,000 .00 0
2015-07-15 Clackson Timothy P (President, R&D, CSO) Option Ex 14,000 .00 0
2015-07-15 Berstein David L (SVP, Chief IP Counsel) Option Ex 8,000 .00 0
2015-07-15 Berger Harvey J M D (Chairman & CEO) Option Ex 36,800 .00 0
2015-05-01 Fitzgerald Edward M (Executive VP, CFO) Sale 60,000 8.80 528,000
2015-05-01 Fitzgerald Edward M (Executive VP, CFO) Option Ex 60,000 7.56 453,600
2015-04-23 Clackson Timothy P (President, R&D, CSO) Sale 123,766 9.50 1,175,777
2015-03-26 Berger Harvey J M D (Chairman & CEO) Option Ex 150,000 7.56 1,134,000
2015-03-23 Cantor Maria E (SVP, Corporate Affairs and HR) Sale 4,033 8.55 34,490
2015-03-23 Haluska Frank (SVP, Clinical R&D, CMO) Sale 3,300 8.55 28,228
2015-03-23 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 3,000 8.55 25,662
2015-03-23 Duvall Martin J (EVP, CCO) Sale 834 8.57 7,144
2015-03-23 Fitzgerald Edward M (Executive VP, CFO) Sale 4,167 8.55 35,632
2015-03-23 Clackson Timothy P (President, R&D, CSO) Sale 6,667 8.55 57,016
2015-03-23 Clackson Timothy P (President, R&D, CSO) Option Ex 13,333 .00 0
2015-03-23 Berstein David L (SVP, Chief IP Counsel) Sale 2,000 8.56 17,118
2015-03-20 Cantor Maria E (SVP, Corporate Affairs and HR) Sale 3,575 8.85 31,628
2015-03-20 Cantor Maria E (SVP, Corporate Affairs and HR) Option Ex 7,333 .00 0
2015-03-20 Haluska Frank (SVP, Clinical R&D, CMO) Sale 3,575 8.85 31,635
2015-03-20 Haluska Frank (SVP, Clinical R&D, CMO) Option Ex 6,000 .00 0
2015-03-20 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Sale 4,000 8.85 35,392
2015-03-20 Bollag Daniel M (Sr. VP, Reg. Affairs & Quality) Option Ex 6,000 .00 0
2015-03-20 Duvall Martin J (EVP, CCO) Sale 4,000 8.85 35,380
2015-03-20 Duvall Martin J (EVP, CCO) Option Ex 1,667 .00 0
2015-03-20 Fitzgerald Edward M (Executive VP, CFO) Sale 5,417 8.84 47,907
2015-03-20 Fitzgerald Edward M (Executive VP, CFO) Option Ex 8,333 .00 0
2015-03-20 Clackson Timothy P (President, R&D, CSO) Sale 5,417 8.84 47,907
2015-03-20 Berstein David L (SVP, Chief IP Counsel) Sale 2,375 8.85 21,025
2015-03-20 Berstein David L (SVP, Chief IP Counsel) Option Ex 4,000 .00 0
2015-03-20 Berger Harvey J M D (Chairman & CEO) Option Ex 34,000 .00 0
2015-03-19 Cantor Maria E (SVP, Corporate Affairs and HR) Sale 9,346 9.00 84,114
2015-03-19 Cantor Maria E (SVP, Corporate Affairs and HR) Option Ex 14,375 1.54 22,137
Go to page:  1   2   3 

Insider trading activities including stock purchases, stock sales, and option exercises of ARIA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ariad Pharmaceuticals Inc (symbol ARIA, CIK number 884731) see the Securities and Exchange Commission (SEC) website.